Mercedon, GSK announce personnel changes!

At the same time, the Division appointed Gu Bo, Chinese business partner of the current Merca East Co-operations Resources, to be promoted to Executive Director, replacing Wang Zhen.
glaxoSmithKline, another multinational pharmaceutical company, also had personnel changes today, with Lin Ziming, head of the South China operations of the Respiratory Business Unit, deciding to leave GSK for personal reasons, the last working day being October 31. qi Xin, vice president of
GSK China and general manager of prescription drugs and vaccines in China, announced his successor to the staff, with he Wei, GSK's current head of national business operations, taking over as head of the South China operations of the respiratory operations department, after which the two will be handed over.
He has joined GSK since 2001 and has served as Regional Manager, Regional Manager, National Sales Director, etc., and has accumulated extensive sales management experience in GSK's hepatitis, respiratory, central nervous and other business areas over the past two decades, and at the end of 2017 he was appointed GSK's Head of National Business Operations in China.
's small partners who follow Big Mimi's push every day should know that this month there are a number of heavyweights in the industry who have changed companies, such as Novarma, which announced earlier this month that Novarma's President for Asia Pacific, Middle East and Africa (APMA) and Novart Group's China president, Yu Xudong, are leaving. Mr. Novart, who took over as president of Novaral Group (China) in the past year, and Luo Yongqing, the former general manager of Gilead China, announced on the 17th of this month that he had joined Tengshengbo Pharmaceuticals as president and general manager of Greater China.
.